ckd complications

in review 5 min read Updated 2026-11-01
ckd complications

Anaemia (KDIGO 2026): screen with CBC, retics, ferritin and TSAT. Iron first, with new non-dialysis thresholds (ferritin <100 + TSAT <40%, or ferritin 100–300 + TSAT <25%). ESA over HIF-PHI; Hb target <115 g/L. MBD: lower phosphate towards normal, limit calcium binders, avoid hypercalcaemia, no routine calcitriol before G4–5. Acidosis: treat to prevent HCO₃⁻ <18 (KDIGO 2024). K⁺ → potassium disorders. Plan KRT or conservative care from 2-year KFRE >40% or eGFR <15–20.


anaemia — KDIGO 2026

screening and work-up

CKD stageHb at least
G3yearly
G4twice a year
G5/G5Devery 3 months
  • Anaemia = Hb <130 g/L (male), <120 g/L (female). First panel: CBC, reticulocytes, ferritin, TSAT
  • Ferritin <45 µg/L or MCV <80 → look for blood loss (GI, gynae, urology)
  • Unexplained → smear, haemolysis screen, CRP, B12/folate, LFTs, SPEP/FLC/urine BJP, TSH, PTH, FOBT
  • Correct reversible causes (iron, B12/folate, infection, hyperparathyroidism, inadequate dialysis, hypothyroidism, haemolysis) before an ESA

iron, ESA and HIF-PHI — doses and titration → ESAs and IV iron

  • Iron first. Non-dialysis/PD: start if ferritin <100 + TSAT <40%, or ferritin 100–300 + TSAT <25% (oral or IV). Haemodialysis: ferritin ≤500 + TSAT ≤30%, IV proactive. Withhold if ferritin >700 or TSAT ≥40%
  • Then ESA if Hb stays low and symptoms or transfusion avoidance justify it — shared decision against stroke, CV events and cancer. Dialysis: start at Hb ≤90–100 g/L; non-dialysis/transplant: individualise
  • Target Hb <115 g/L (1D). ESA over HIF-PHI first line (2D)
  • Hyporesponsive → rework the reversible causes above before escalating
  • Transfusion on symptoms, not a number; avoid in transplant candidates (allosensitisation)
  • General iron-deficiency work-up and formulations → iron deficiency
what changed (2012 → 2026)

Non-dialysis iron thresholds moved from “ferritin ≤500 and TSAT ≤30%” to ferritin <100 with TSAT <40%, or ferritin 100–300 with TSAT <25%. The ≤500/≤30% rule now applies to haemodialysis only. The Hb ceiling of 115 g/L is unchanged. CSN 2015 (older) advised screening for anaemia only once eGFR <30.


CKD–mineral and bone disorder — KDIGO 2017

monitoring (from G3a)

stageCa, PO₄PTHALP
G3a–3b6–12 monthlyby baseline and progression—
G43–6 monthly6–12 monthlyyearly
G5/G5D1–3 monthly3–6 monthlyyearly
  • 25(OH)D may be measured; correct deficiency as for the general population
  • Act on trends, not single values. Use Ca and PO₄ separately; Ca × P product isn’t recommended
  • Known vascular or valvular calcification = highest CV risk. Lateral abdominal X-ray or echo are acceptable screens

phosphate and calcium

  • Lower phosphate towards the normal range when it is persistently or progressively high (2C). Treating early or to normal isn’t the goal
  • Avoid hypercalcaemia (2C); restrict calcium-based binders (2B); never long-term aluminium (1C) → phosphate binders
  • Limit dietary phosphate, especially additives in processed food (2D). Dialysis → increase dialytic removal
  • Dialysate Ca 1.25–1.50 mmol/L

PTH

  • Non-dialysis: optimal PTH unknown. Rising or above normal → look for high phosphate, low calcium, high phosphate intake, vitamin D deficiency (2C)
  • No routine calcitriol or analogues in G3a–G5 (2C). Reserve for G4–5 with severe, progressive hyperparathyroidism
  • Dialysis: iPTH ≈2–9× the upper limit of normal (2C); marked changes in either direction within the range → start or change therapy (2C). Lower PTH with calcimimetic (cinacalcet), calcitriol or analogue, or a combination (2B)
  • Refractory severe hyperparathyroidism → parathyroidectomy (2B)

bone

  • G1–2, or G3 with normal PTH: treat osteoporosis as for the general population
  • G3a–G5D with MBD lab abnormalities + low BMD or fracture → individualise; consider bone biopsy before antiresorptives
  • BMD testing if it changes management (2B)

metabolic acidosis — KDIGO 2024

  • Treat (drug ± diet) to prevent HCO₃⁻ <18 mmol/L in adults
  • Don’t overshoot the upper normal limit; watch BP, K⁺ and volume (sodium load) → sodium bicarbonate
  • The old KDIGO 2012 aim of “keep HCO₃⁻ ≥22” was replaced by this lower, practice-point threshold

other complications

hyperkalaemia

  • Measurement varies (serum vs plasma, time of day, haemolysis)
  • G3–G5 with prior hyperkalaemia → limit foods rich in bioavailable K⁺ (processed foods), renal dietitian
  • Keep RASi/MRA going with diuretics or binders; action bands by K⁺ level (UKKA, Diabetes Canada) → potassium disorders, potassium binders

gout and urate — KDIGO 2024

  • Symptomatic hyperuricaemia → urate lowering (1C); consider after the first gout attack (especially urate >535 µmol/L). Xanthine oxidase inhibitor over uricosurics
  • Acute flare: low-dose colchicine or steroid (intra-articular or oral) over NSAIDs
  • Asymptomatic hyperuricaemia: don’t treat to slow CKD (2D)

cardiovascular and AF

uraemic symptoms, nutrition, KRT planning

  • Ask about appetite, nausea, fatigue and pruritus at each visit (validated tool)
  • Screen for malnutrition twice a year if G4–5, age >65, weight loss or frailty
  • Plan pre-emptive transplant and/or dialysis access when eGFR <15–20 or 2-year KFRE >40%
  • Start dialysis on a composite of symptoms and signs, not eGFR alone. Usually eGFR 5–10 when one of these is present:
    • uraemic serositis, encephalopathy or pruritus
    • refractory acid–base/K⁺ problems
    • uncontrollable volume or BP
    • declining nutrition or cognition
  • Urgent dialysis (AEIOU: acidosis, electrolytes, ingestions, overload, uraemia) → dialysis overview
  • Conservative kidney management (no KRT) is a legitimate choice. Offer it alongside KRT, with advance care planning

Prepared 2026-11-01. Not yet verified — check every number against the sources.

Key references

+2 more sources

Suggest a correction ckd complications